The story back then… Cannabis’ (Marijuana) use as medicine dates back to 4000 BC in China. During the 19th century and till early 20th century, marijuana was used globally, to treat various illnesses such as migraine, neuropathic pain, musculoskeletal pain and in childbirth.2 In Canada, cannabis was added to the Confidential Restricted List in 1923 under the Narcotics Drug Act Amendment Bill.3 Cannabis was listed under Schedule 1 drugs and made illegal in
value-based care
Healthcare is an expanding and complex industry. The ageing population, higher prevalence of chronic diseases, advances in digital technologies, highly efficacious and expensive drugs have led to an increase in the healthcare demand and expenditures. The global health care spending projected at $ 10.05 Trillion by 2022 represents 2018-2022 CAGR of 5.4%, a considerable rise from 2.9% in 2013–20171 Having said that, the healthcare systems are shifting from volume-based care (fee for service) to value
It’s been almost 3 years since the British voted 52-48% to leave the EU on 23rd June 2016.12  Given the lack of clarity and ensuing uncertainty, the pharmaceutical companies have been planning for a worst-case scenario i.e. no-deal. We will look at the most important (subjectively assessed) implications of a no-deal Brexit scenario for Pharmaceutical industry. Before I discuss the potential consequences of a no-deal Brexit, here are some metrics that reflect the importance of
3D Printing
Biofabrication can be defined as the production of complex living and non-living biological products from raw materials such as living cells, molecules, extracellular matrices, and biomaterials. – Mironov et al., 2015. First things first…What´s 3D printing? The standard two-dimensional (2D) printing is the act of depositing ink on a 2D surface of a medium e.g. paper, cloth, plastic etc. This type of printing involves the horizontal and vertical directions generally known as X and Y
Oncology R&D investment has been consistently increasing. A case in point: Of the 65000 trials registered on, there are approx. 19000 product related ongoing trials. It´s noteworthy that a trial´s probability of success hasn´t increased over the years i.e. most of these trials face a higher risk of failure than ever before. A few highlights from 2018: 15 new drugs launched for 17 indications Currently >700 companies are undertaking clinical development activities; of these
Rx Usage
The latest report from the IQVIA™ Institute for Human Data Science presents the 2018 Medicines Use and Spending in the U.S. The report provides extensive metrics on drug usage and its cost to the US Healthcare system. We discuss some of the interesting findings of this report. 2018 witnessed a 2.7% growth in the total prescriptions dispensed and an increase of 4.5% in net spending (defined as the amount received by pharmaceutical manufacturers after rebates,